Researchers at The University of Texas MD Anderson Cancer Center identified a strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6.
Research from the University of Pittsburgh explains why metastatic uveal melanoma is resistant to conventional immunotherapies and how adoptive therapy, which involves growing a patient’s T cells outside the body before reinfusing them, can successfully treat this rare and aggressive cancer.
